Doetsch Grether has received valuation services
Located in the heart of Basel, Switzerland, Doetsch Grether AG is a medium-sized, family-owned company with traditional values that specializes in the marketing and distribution of products in the pharma, OTC and consumer care segments.
Doetsch Grether’s portfolio consists of its own brands, such as the famous Grether’s Pastilles®, neo-angin® and Sulgan®N, as well as distribution brands that include Magnesium-Diasporal®, Tiger Balm® and Pearl Drops®, which are successfully sold throughout Switzerland.
Oaklins’ team in Switzerland has repeatedly advised Doetsch Grether on valuation topics, contract drafting and the preparation of second opinions in connection with various acquisition projects.



Lukas Grimm
CFO, Doetsch Grether AG
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more